Affiliation:
1. V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk science center of the siberian Branch of the Russian Academy of Sciences
2. Institute of Chemical Biology and Fundamental Medicine of the SiberianBranch of the Russian Academy of Sciences
3. V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
Abstract
Purpose of the study: to evaluate the feasibility of using functional analogues of protein antibodies – dNa/ RNa aptamers in diagnostics, treatment and prognosis of human brain glial tumors.Material and Methods. The relevant literature sources were searched in scopus, Web of science, pubmed, elibrary with inclusion of publications from 2000 to 2023. sixty articles are presented in the review.Results. The analysis of the literature devoted to classification, diagnostics and therapy of brain glioblastomas was carried out and the feasibility of using for in vivo diagnostics and therapy of this disease aptamers, which are molecular recognition elements based on DNA/RNA oligonucleotides, capable of binding to the given molecular targets and distinguishing even separate functional groups in them, was studied. A list of aptamers to human glial brain tumors and their molecular targets that can be used for diagnostics and therapy of glioblastoma, including tumor imaging by pet/ct, mRi, plasmon resonance, fluorescence and confocal microscopy, etc., is presented. literature data suggest that DNA/RNA aptamers can be used to search for circulating tumor cells in the blood of glioblastoma patients, to target therapeutic drugs to the tumor and to inhibit tumor growth.Conclusion. Brain glioblastoma is a heterogeneous tumor consisting of cells at different stages of malignancy and, accordingly, with a different set of oncogenes. For this reason, a multitarget strategy that includes combined suppression of angiogenesis, invasion, metastasis, proliferation and survival of tumor cells should be proposed for the therapy of this disease. DNA/RNA aptamers tailored to key proteins involved in oncogenic transformation may be suitable candidates for the implementation of multitarget therapy for brain glioblastoma.
Publisher
Tomsk Cancer Research Institute
Reference60 articles.
1. Park Y.W., Vollmuth P., Foltyn-Dumitru M., Sahm F., Ahn S.S., Chang J.H., Kim S.H. The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas. J Magn Reson Imaging. 2023; 58(3): 677–89. doi: 10.1002/jmri.28743.
2. Sergeev N.I., Rebrikova V.A., Kotlayrov P.M., SolodkII V.A. Magnetic resonance imaging with perfusion imaging in the diagnosis of cerebral glioblastomas (literature review). Bulletin of the Russian Scientific Center for Radiology. 2021; 2(1): 45–59. (in Russian).
3. Aquino D., Di Stefano A.L., Scotti A., Cuppini L., Anghileri E., Finocchiaro G., Bruzzone M.G., Eoli M. Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS One. 2014; 9(3). doi: 10.1371/journal.pone.0090535.
4. Rozumenko V.D. Brain tumors: current state of the problem. Alushta: III Congress of Neurosurgeons of Ukraine, 2003]. [cited 2023 Aug 1]. URL: https://health-ua.com/article/18896-opuholi-golovnogomozga-sovremennoe-sostoyanie-problemy. (in Russian).
5. Brown T.J., Brennan M.C., Li M., Church E.W., Brandmeir N.J., Rakszawski K.L., Patel A.S., Rizk E.B., Suki D., Sawaya R., Glantz M. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2016; 2(11): 1460–9. doi: 10.1001/jamaoncol.2016.1373.